

# ***Meet The Professor***

## **Optimizing the Management of Multiple Myeloma**

**Thursday, January 26, 2023  
5:00 PM – 6:00 PM ET**

**Faculty**

**Noopur Raje, MD**

**Moderator**

**Neil Love, MD**

## Commercial Support

This activity is supported by educational grants from AbbVie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.

## Dr Love — Disclosures

**Dr Love** is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.


# Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

# Dr Raje — Disclosures

<b>Advisory Committee</b>	bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Immuneel Therapeutics, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Pharmaceuticals USA Inc
<b>Contracted Research</b>	bluebird bio
<b>Steering Committee</b>	Amgen Inc, Roche Laboratories Inc

# We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

# Familiarizing Yourself with the Zoom Interface

## Expand chat submission box

The screenshot displays a Zoom meeting interface. At the top, there's a header bar with participant names: RTP Coordinat..., Kirsten Miller, RTP Mike Rivera, and Lisa Suarez. Below this, a slide titled "Meet The Professor Program Participating Faculty" is shown, featuring six faculty members with their photos and titles. To the right, a chat window is open, showing messages from "Me to Panelists" and "Me to Panelists and Attendees". A red arrow points to the white line above the chat submission box, indicating where to drag to expand the box.

**Meet The Professor Program Participating Faculty**

- Nancy L Bartlett, MD**  
Professor of Medicine  
Koman Chair in Medical Oncology  
Washington University School of Medicine  
St Louis, Missouri
- Jonathan W Friedberg, MD, MMSc**  
Samuel E Durand Professor of Medicine  
Director, James P Wilmot Cancer Institute  
University of Rochester  
Rochester, New York
- Carla Casulo, MD**  
Associate Professor of Medicine  
Division of Hematology/Oncology  
Director, Hematology/Oncology Fellowship Program  
University of Rochester  
Wilmot Cancer Institute  
Rochester, New York
- Brian T Hill, MD, PhD**  
Director, Lymphoid Malignancy Program  
Cleveland Clinic Taussig Cancer Institute  
Cleveland, Ohio
- Christopher R Flowers, MD, MS**  
Chair, Professor  
Department of Lymphoma/Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas
- Brad S Kahl, MD**  
Professor of Medicine  
Washington University School of Medicine  
Director, Lymphoma Program  
Siteman Cancer Center  
St Louis, Missouri

**Chat**

Me to Panelists 4:31 PM

Welcome and thank you for attending! To access the slides from today's session please use the link below.  
[http://images.researchtopractice.com/2021/Meetings/Slides/MTP\\_ToGo\\_CLL\\_2021\\_April1.pdf](http://images.researchtopractice.com/2021/Meetings/Slides/MTP_ToGo_CLL_2021_April1.pdf)

Me to Panelists and Attendees 4:32 PM

Welcome and thank you for attending! To access the slides from today's session please use the link below.  
[http://images.researchtopractice.com/2021/Meetings/Slides/MTP\\_ToGo\\_CLL\\_2021\\_April1.pdf](http://images.researchtopractice.com/2021/Meetings/Slides/MTP_ToGo_CLL_2021_April1.pdf)


To: Panelists and Attendees

Type message here...

Drag the white line above the submission box up to create more space for your message.

# Familiarizing Yourself with the Zoom Interface

## Increase chat font size



**Press Command (for Mac) or Control (for PC) and the + symbol.  
You may do this as many times as you need for readability.**



# Clinicians in the Audience, Please Complete the Pre- and Postmeeting Surveys

The screenshot shows a Zoom meeting window. At the top, a row of seven participant video thumbnails is visible. The main content area on the left displays a presentation slide with the following text:   
**Meet The Profe**  
**Optimizing the Selection and**  
**of Therapy for Patients with**  
**Gastrointestinal Ca**  
  
**Wednesday, August 25,**  
**5:00 PM – 6:00 PM E**  
  
**Faculty**  
**Wells A Messersmith,**  
  
**Moderator**  
**Neil Love, MD**  
  
The RTP Research to Practice logo is in the bottom right corner of the slide. A 'Quick Survey' pop-up window is centered over the slide, listing several treatment options with radio buttons for selection. To the right of the main content area is a 'Participants (10)' sidebar showing a list of names with their respective status icons (microphone, video, chat). At the bottom of the window is a Zoom toolbar with icons for Join Audio, Start Video, Invite, Participants, Share, Chat, Record, and a red 'Leave Meeting' button.

**Quick Survey**

- ☐ Ceritinib +/- dexamethasone
- ☐ Pomalidomide +/- dexamethasone
- ☐ Ceritinib + pomalidomide +/- dexamethasone
- ☐ Elotuzumab + lenalidomide +/- dexamethasone
- ☐ Elotuzumab + pomalidomide +/- dexamethasone
- ☐ Daratumumab + lenalidomide +/- dexamethasone
- ☐ Daratumumab + pomalidomide +/- dexamethasone
- ☐ Daratumumab + bortezomib +/- dexamethasone
- ☐ Isaxozim + Rd
- ☐ Other

**Participants (10)**

- JS John Smith
- MM Mary Major
- RM Richard Miles
- JN John Noakes
- AS Alice Suarez
- JP Jane Perez
- RS Robert Stiles
- JF Juan Fernandez
- AK Ashok Kumar
- JS Jeremy Smith

The screenshot shows a Zoom meeting window. At the top, a row of seven participant video thumbnails is visible. The main content area on the left displays a presentation slide with the following text:   
**Regulatory and reimbursement issues aside, what**  
**would you recommend for a 65-year-old patient**  
**nephrectomy for clear cell renal cell carcinoma (c**  
**follow-up 3 years later is found to have asymptomatic**  
**(PS 0)?**  
  
Below the text is a numbered list of eight options. A 'Quick Poll' pop-up window is centered over the list, showing the same eight options with radio buttons for selection. To the right of the main content area is a 'Participants (10)' sidebar showing a list of names with their respective status icons. At the bottom of the window is a Zoom toolbar with icons for Join Audio, Start Video, Invite, Participants, Share, Chat, Record, and a red 'Leave Meeting' button.

**Quick Poll**

1. Nivolumab/ipilimumab
2. Avelumab/axitinib
3. Pembrolizumab/axitinib
4. Pembrolizumab/lenvatinib
5. Nivolumab/cabozantinib
6. Tyrosine kinase inhibitor (TKI) monotherapy
7. Anti-PD-1/PD-L1 monotherapy
8. Other

**Participants (10)**

- JS John Smith
- MM Mary Major
- RM Richard Miles
- JN John Noakes
- AS Alice Suarez
- JP Jane Perez
- RS Robert Stiles
- JF Juan Fernandez
- AK Ashok Kumar
- JS Jeremy Smith


# ONCOLOGY TODAY

WITH DR NEIL LOVE

## BCMA-Directed Therapies for Multiple Myeloma



DR AMRITA KRISHNAN  
CITY OF HOPE CANCER CENTER



# ***Meet The Professor***

## **Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer**

**Tuesday, January 31, 2023  
5:00 PM – 6:00 PM ET**

**Faculty**

**Komal Jhaveri, MD**

**Moderator**

**Neil Love, MD**

# **Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology**

*A Multitumor CME/MOC-Accredited Live Webinar Series*

## **Hodgkin and Non-Hodgkin Lymphomas**

**Wednesday, February 1, 2023  
5:00 PM – 6:00 PM ET**

### **Faculty**

**Christopher R Flowers, MD, MS  
Laurie H Sehn, MD, MPH**

### **Moderator**

**Neil Love, MD**

# Inside the Issue — Optimizing the Management of Adverse Events Associated with BTK Inhibitors

*A CME/MOC-Accredited Virtual Event*

**Thursday, February 2, 2023**

**5:00 PM – 6:00 PM ET**

## **Faculty**

**Farrukh T Awan, MD**

**Kerry A Rogers, MD**

## **Moderator**

**Neil Love, MD**

# Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer

*A CME/MOC-Accredited Virtual Event*

**Wednesday, February 8, 2023**

**5:00 PM – 6:00 PM ET**

## **Faculty**

**Kathy D Miller, MD**

**Ann Partridge, MD, MPH**

## **Moderator**

**Neil Love, MD**

# Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Renal Cell Carcinoma

*Part 1 of a 3-Part CME Symposium Series Held in Conjunction  
with the 2023 ASCO Genitourinary Cancers Symposium*

**Wednesday, February 15, 2023**

**7:15 PM – 8:45 PM PT (10:15 PM – 11:45 PM ET)**

## **Faculty**

**Prof Laurence Albiges, MD, PhD**

**Thomas Powles, MBBS, MRCP, MD**

**Toni K Choueiri, MD**

## **Moderator**

**Brian Rini, MD**

# Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Prostate Cancer

*Part 2 of a 3-Part CME Symposium Series Held in Conjunction  
with the 2023 ASCO Genitourinary Cancers Symposium*

**Thursday, February 16, 2023**

**7:15 PM – 9:15 PM PT (10:15 PM – 12:15 AM ET)**

## **Faculty**

**Emmanuel S Antonarakis, MD**

**Maha Hussain, MD, FACP, FASCO**

**Prof Karim Fizazi, MD, PhD**

**Matthew R Smith, MD, PhD**

## **Moderator**

**Alan H Bryce, MD**



# Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Urothelial Bladder Cancer

*Part 3 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Genitourinary Cancers Symposium*

**Friday, February 17, 2023**

**6:30 PM – 8:00 PM PT (9:30 PM – 11:00 PM ET)**

## **Faculty**

**Matthew D Galsky, MD**

**Arlene Siefker-Radtke, MD**

**Jonathan E Rosenberg, MD**

## **Moderator**

**Elisabeth I Heath, MD**

***Thank you for joining us!***

***CME and MOC credit information will be emailed to each participant within 5 business days.***

# ***Meet The Professor***

## **Optimizing the Management of Multiple Myeloma**

**Noopur Raje, MD**

Director, Center for Multiple Myeloma  
Massachusetts General Hospital Cancer Center  
Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts

# Meet The Professor Program Participating Faculty



**Rafael Fonseca, MD**

Chief Innovation Officer  
Getz Family Professor of Cancer  
Distinguished Mayo Investigator  
Mayo Clinic in Arizona  
Phoenix, Arizona



**Sagar Lonial, MD**

Chair and Professor  
Department of Hematology and Medical Oncology  
Anne and Bernard Gray Family Chair in Cancer  
Chief Medical Officer  
Winship Cancer Institute  
Emory University School of Medicine  
Atlanta, Georgia



**Shaji K Kumar, MD**

Mark and Judy Mullins Professor  
of Hematological Malignancies  
Consultant, Division of Hematology  
Professor of Medicine  
Mayo Clinic  
Rochester, Minnesota



**Joseph Mikhael, MD, MEd**

Professor, Applied Cancer Research and Drug Discovery  
Translational Genomics Research Institute (TGen)  
City of Hope Cancer Center  
Chief Medical Officer  
International Myeloma Foundation  
Consultant Hematologist and Director, Myeloma  
Research, Phase 1 Program  
HonorHealth Research Institute  
Adjunct Professor, College of Health Solutions  
Arizona State University  
Phoenix, Arizona



**Ola Landgren, MD, PhD**

Professor of Medicine  
Leader, Experimental Therapeutics Program  
Leader, Myeloma Division  
Co-Leader of Tumor Biology Program  
Sylvester Comprehensive Cancer Center  
University of Miami  
Miami, Florida

# *Meet The Professor Program Participating Faculty*



**Noopur Raje, MD**

Director, Center for Multiple Myeloma  
Massachusetts General Hospital Cancer Center  
Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts



**MODERATOR**

**Neil Love, MD**


Research To Practice



**Paul G Richardson, MD**

Clinical Program Leader and Director of Clinical  
Research  
Jerome Lipper Multiple Myeloma Center  
Dana-Farber Cancer Institute  
RJ Corman Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts

# We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

# Clinicians in the Audience, Please Complete the Pre- and Postmeeting Surveys

The screenshot shows a Zoom meeting window. At the top, a row of seven participant video thumbnails is visible. The main content area displays a presentation slide with the following text:

**Meet The Professionals**  
**Optimizing the Selection and Timing of Therapy for Patients with Gastrointestinal Cancer**  
**Wednesday, August 25, 2021**  
**5:00 PM – 6:00 PM EST**  
**Faculty**  
**Wells A Messersmith, MD**  
**Moderator**  
**Neil Love, MD**

A "Quick Survey" pop-up window is overlaid on the slide, listing various treatment combinations with radio button options:

- ☐ Ceritinib +/- dexamethasone
- ☐ Pomalidomide +/- dexamethasone
- ☐ Ceritinib + pomalidomide +/- dexamethasone
- ☐ Elotuzumab + lenalidomide +/- dexamethasone
- ☐ Elotuzumab + pomalidomide +/- dexamethasone
- ☐ Daratumumab + lenalidomide +/- dexamethasone
- ☐ Daratumumab + pomalidomide +/- dexamethasone
- ☐ Daratumumab + bortezomib +/- dexamethasone
- ☐ Isaxozim + Rd

The "Participants (10)" list on the right side of the window includes:

- John Smith
- Mary Major
- Richard Miles
- John Noakes
- Alice Suarez
- Jane Perez
- Robert Stiles
- Juan Fernandez
- Ashok Kumar
- Jeremy Smith

The bottom toolbar contains icons for Join Audio, Start Video, Invite, Participants, Share, Chat, Record, and a red "Leave Meeting" button.

The screenshot shows a Zoom meeting window. At the top, a row of seven participant video thumbnails is visible. The main content area displays a presentation slide with the following text:

**Regulatory and reimbursement issues aside, which treatment would you recommend for a 65-year-old patient with clear cell renal cell carcinoma (ccRCC) if follow-up 3 years later is found to have asymptomatic (PS 0)?**

A "Quick Poll" pop-up window is overlaid on the slide, listing treatment options with radio button options:

- ☐ Nivolumab/ipilimumab
- ☐ Avelumab/axitinib
- ☐ Pembrolizumab/axitinib
- ☐ Pembrolizumab/lenvatinib
- ☐ Nivolumab/cabozantinib
- ☐ Tyrosine kinase inhibitor (TKI) monotherapy
- ☐ Anti-PD-1/PD-L1 monotherapy
- ☐ Other

The "Participants (10)" list on the right side of the window includes:

- John Smith
- Mary Major
- Richard Miles
- John Noakes
- Alice Suarez
- Jane Perez
- Robert Stiles
- Juan Fernandez
- Ashok Kumar
- Jeremy Smith

The bottom toolbar contains icons for Join Audio, Start Video, Invite, Participants, Share, Chat, Record, and a red "Leave Meeting" button.




# ONCOLOGY TODAY

WITH DR NEIL LOVE

## BCMA-Directed Therapies for Multiple Myeloma



DR AMRITA KRISHNAN  
CITY OF HOPE CANCER CENTER





# ***Meet The Professor***

## **Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer**

**Tuesday, January 31, 2023  
5:00 PM – 6:00 PM ET**

**Faculty**

**Komal Jhaveri, MD**

**Moderator**

**Neil Love, MD**

# **Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology**

*A Multitumor CME/MOC-Accredited Live Webinar Series*

## **Hodgkin and Non-Hodgkin Lymphomas**

**Wednesday, February 1, 2023  
5:00 PM – 6:00 PM ET**

### **Faculty**

**Christopher R Flowers, MD, MS  
Laurie H Sehn, MD, MPH**

### **Moderator**

**Neil Love, MD**

# Inside the Issue — Optimizing the Management of Adverse Events Associated with BTK Inhibitors

*A CME/MOC-Accredited Virtual Event*

**Thursday, February 2, 2023**

**5:00 PM – 6:00 PM ET**

## **Faculty**

**Farrukh T Awan, MD**

**Kerry A Rogers, MD**

## **Moderator**

**Neil Love, MD**

# Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer

*A CME/MOC-Accredited Virtual Event*

**Wednesday, February 8, 2023**

**5:00 PM – 6:00 PM ET**

## **Faculty**

**Kathy D Miller, MD**

**Ann Partridge, MD, MPH**

## **Moderator**

**Neil Love, MD**

# Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Renal Cell Carcinoma

*Part 1 of a 3-Part CME Symposium Series Held in Conjunction  
with the 2023 ASCO Genitourinary Cancers Symposium*

**Wednesday, February 15, 2023**

**7:15 PM – 8:45 PM PT (10:15 PM – 11:45 PM ET)**

## **Faculty**

**Prof Laurence Albiges, MD, PhD**

**Thomas Powles, MBBS, MRCP, MD**

**Toni K Choueiri, MD**

## **Moderator**

**Brian Rini, MD**

# **Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Prostate Cancer**

*Part 2 of a 3-Part CME Symposium Series Held in Conjunction  
with the 2023 ASCO Genitourinary Cancers Symposium*

**Thursday, February 16, 2023**

**7:15 PM – 9:15 PM PT (10:15 PM – 12:15 AM ET)**

## **Faculty**

**Emmanuel S Antonarakis, MD**

**Maha Hussain, MD, FACP, FASCO**

**Prof Karim Fizazi, MD, PhD**

**Matthew R Smith, MD, PhD**

## **Moderator**

**Alan H Bryce, MD**

# Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Urothelial Bladder Cancer

*Part 3 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Genitourinary Cancers Symposium*

**Friday, February 17, 2023**

**6:30 PM – 8:00 PM PT (9:30 PM – 11:00 PM ET)**

## **Faculty**

**Matthew D Galsky, MD**

**Arlene Siefker-Radtke, MD**

**Jonathan E Rosenberg, MD**

## **Moderator**

**Elisabeth I Heath, MD**

# ***Meet The Professor***

## **Optimizing the Management of Multiple Myeloma**

**Noopur Raje, MD**

Director, Center for Multiple Myeloma  
Massachusetts General Hospital Cancer Center  
Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts



## Commercial Support

This activity is supported by educational grants from AbbVie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.

## Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

# Dr Raje — Disclosures

<b>Advisory Committee</b>	bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Immuneel Therapeutics, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Pharmaceuticals USA Inc
<b>Contracted Research</b>	bluebird bio
<b>Steering Committee</b>	Amgen Inc, Roche Laboratories Inc



**Warren S Brenner, MD**  
Lynn Cancer Institute  
Boca Raton, Florida



**Yanjun Ma, MD**  
Tennessee Oncology  
Murfreesboro, Tennessee



**Jennifer L Dallas, MD**  
Oncology Specialists of Charlotte  
Charlotte, North Carolina



**Neil Morganstein, MD**  
Atlantic Health System  
Summit, New Jersey



**Ranju Gupta, MD**  
Lehigh Valley Topper Cancer Institute  
Bethlehem, Pennsylvania



**Vignesh Narayanan, MD**  
Colorado Permanente Medical Group  
Lone Tree, Colorado



**Hans Lee, MD**  
The University of Texas  
MD Anderson Cancer Center  
Houston, Texas



**Swati Vishwanathan, MD**  
WVU Medicine  
Bridgeport, West Virginia

# Meet The Professor with Dr Raje

## **INTRODUCTION**

### **MODULE 1: Case Presentations, Part 1**

### **MODULE 2: Faculty Survey**

### **MODULE 3: Case Presentations, Part 2**

### **MODULE 4: Journal Club with Dr Raje**

# Meet The Professor with Dr Raje

## INTRODUCTION

**MODULE 1: Case Presentations, Part 1**

**MODULE 2: Faculty Survey**

**MODULE 3: Case Presentations, Part 2**

**MODULE 4: Journal Club with Dr Raje**

## Editorial

# Leaving Lytic Lesions—Is There New Role for Radiation in Multiple Myeloma in the CAR T Era?

Hazim S. Ababneh, MD<sup>a</sup>

Noopur S. Raje, MD<sup>b</sup>

Andrew J. Yee, MD<sup>b</sup>


Chirayu G. Patel, MD, MPH<sup>a\*</sup>

# **Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy**

Waldschmidt JM et al.  
ASH 2022;Abstract 4456.


*Review*

# Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

Zachary S. Bernstein <sup>1</sup> , E. Bridget Kim <sup>2</sup> and Noopur Raje <sup>1,3,\*</sup>



# Overview of the Interplay Between Multiple Myeloma Cells, Osteoclasts and Osteoblasts, Which Favors Bone Resorption



# Phase III Randomized Studies of Denosumab versus Zoledronic Acid in Solid and Hematologic Malignancies

Treatment <sup>a</sup>	Disease Group	<i>n</i>	Median Time to First SRE (Months)	Hazard Ratio	Renal Toxicity <sup>d</sup>
Denosumab	Breast cancer [122]	1026	NR <sup>c</sup>	0.82 (0.71–0.95); <i>p</i> < 0.001	4.9%
	Prostate cancer [121]	950	20.7	0.82 (0.71–0.95); <i>p</i> = 0.0002	16%
	Solid tumors <sup>b</sup> [120]	886	20.6	0.82 (0.71–0.98); <i>p</i> = 0.0007	8.3%
	Multiple Myeloma [123]	859	22.83	0.98 (0.85–1.14); <i>p</i> = 0.01	10%
Zoledronic acid	Breast cancer [122]	1020	26.4	—	8.5%
	Prostate cancer [121]	951	17.1	—	15%
	Solid tumors [120]	890	16.3	—	10.9%
	Multiple Myeloma [123]	859	23.98	—	17.1%

<sup>a</sup> Treatment included subcutaneous denosumab 120 mg and intravenous placebo every four weeks or subcutaneous placebo and intravenous ZA 4 mg. <sup>b</sup> Tumors including lung and multiple myeloma and excluding breast and prostate. <sup>c</sup> Endpoint not reached (NR). <sup>d</sup> Incidence of renal adverse event and elevations in serum creatinine.

REGULAR ARTICLE

2021 February 9;5(3):725-36.



blood advances®

# Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study

Evangelos Terpos,<sup>1</sup> Noopur Raje,<sup>2,3</sup> Peter Croucher,<sup>4,5</sup> Ramon Garcia-Sanz,<sup>6</sup> Xavier Leleu,<sup>7</sup> Waltraud Pasteiner,<sup>8</sup> Yang Wang,<sup>9</sup> Anthony Glennane,<sup>9</sup> Jude Canon,<sup>9</sup> and Charlotte Pawlyn<sup>10</sup>

LEUKEMIA & LYMPHOMA

2022, VOL. 63, NO. 13, 3249–3252

<https://doi.org/10.1080/10428194.2022.2115840>



Taylor & Francis  
Taylor & Francis Group

LETTER TO THE EDITOR

## Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma

Matthew M. Lei<sup>a</sup> , Erica Tavares<sup>a</sup>, Evan Buzgo<sup>b</sup>, Uvette Lou<sup>a</sup> , Noopur Raje<sup>c</sup> and Andrew J. Yee<sup>c</sup> 

# Meet The Professor with Dr Raje

## INTRODUCTION

### MODULE 1: Case Presentations, Part 1

- Dr Vishwanathan: 80-year-old man who presents with renal failure (creatinine = 7) and standard-risk multiple myeloma (MM)
- Dr Brenner: 67-year-old man with a large sternal plasmacytoma
- Dr Lee: 62-year-old man who presents with multiple bone lesions and t(4;14), (1q21+) MM
- Dr Ma: 37-year-old man with standard-risk MM who receives RVd > autologous stem cell transplant and has been on maintenance lenalidomide for 3.5 years
- Dr Morganstein: 66-year-old asymptomatic woman with quadruple-refractory MM with multiple prior serious infections

### MODULE 2: Faculty Survey

### MODULE 3: Case Presentations, Part 2

### MODULE 4: Journal Club with Dr Raje

## Case Presentation: 80-year-old man who presents with renal failure (creatinine = 7) and standard-risk MM



**Dr Swati Vishwanathan (Bridgeport, West Virginia)**



## Case Presentation: 67-year-old man with a large sternal plasmacytoma



**Dr Warren Brenner (Boca Raton, Florida)**

## Case Presentation: 62-year-old man who presents with multiple bone lesions and t(4;14), (1q21+) MM



**Dr Hans Lee (Houston, Texas)**




## HEMATOLOGIC MALIGNANCIES

# How to Treat High-Risk Myeloma at Diagnosis and Relapse


Jessica Caro, MD<sup>1</sup>; Samer Al Hadidi, MD, MS, FACP<sup>2</sup>; Saad Usmani, MD, MBA, FACP<sup>3</sup>; Andrew J. Yee, MD<sup>4</sup>; Noopur Raje, MD<sup>4</sup>; and Faith E. Davies, MBBCh, MRCP, FRCPATH<sup>1</sup>

*Am Soc Clin Oncol Educ Book 2021 March;41:291-309.*

# Proposed Modifications to Revised International Scoring System to Incorporate Additional High-Risk Features



# Treatment Approach for Patients with High-Risk, Newly Diagnosed Multiple Myeloma



**Case Presentation: 37-year-old man with standard-risk MM who receives RVd > autologous stem cell transplant and has been on maintenance lenalidomide for 3.5 years**



**Dr Yanjun Ma (Murfreesboro, Tennessee)**


*Hematology Am Soc Hematol Educ Program 2021 December 10;2021(1):37-45.*

# Minimal residual disease in multiple myeloma: why, when, where

**Andrew J. Yee<sup>1,2</sup> and Noopur Raje<sup>1,2</sup>**

<sup>1</sup>Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; and <sup>2</sup>Harvard Medical School, Boston, MA

# Minimum Residual Disease (MRD) to Guide Treatment





## Case Presentation: 66-year-old asymptomatic woman with quadruple-refractory MM with multiple prior serious infections



**Dr Neil Morganstein (Summit, New Jersey)**

# US Marketing Authorization to Be Withdrawn for Belantamab Mafodotin for Multiple Myeloma

Press Release: November 22, 2022

Following a request from the FDA, the process for withdrawal of the US marketing authorization for belantamab mafodotin-blmf has begun. This move comes shortly after it was disclosed that the antibody-drug conjugate failed to show superiority over the combination of pomalidomide and low-dose dexamethasone in the confirmatory Phase III DREAMM-3 trial for patients with relapsed or refractory multiple myeloma.

Earlier this month it was reported that in the DREAMM-3 study median progression-free survival was 11.2 months with belantamab mafodotin and 7 months with pomalidomide and dexamethasone, with a hazard ratio (HR) of 1.03 for the primary endpoint. Meanwhile, median overall survival was 21.2 months with belantamab mafodotin and 21.1 months with pomalidomide and dexamethasone, with a HR of 1.14.

Belantamab mafodotin is also being evaluated in the late-stage DREAMM-7 and DREAMM-8 trials investigating earlier use of the drug in combination with novel therapies and standard treatments.

Belantamab mafodotin remains available in other countries.



# Melphalan Flufenamide Withdrawn from the US Market

Press Release: October 26, 2021

On October 22, [the company] announced its decision to withdraw melphalan flufenamide, a first-in-class peptide-drug conjugate, from the market in the United States, following results from the Phase III OCEAN study in patients with relapsed or refractory multiple myeloma. The decision to withdraw was made after interactions and dialogue with the U.S. Food and Drug Administration (FDA); melphalan flufenamide was granted accelerated approval by the agency on February 26, 2021.

In a press release from the company, representatives wrote, “During our dialogue with FDA, it has become evident that the FDA does not consider that the phase III OCEAN study meets the criteria of a confirmatory study.”

# FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

**Press Release: October 25, 2022**

The Food and Drug Administration granted accelerated approval to teclistamab-cqyv, the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Teclistamab-cqyv was evaluated in MajesTEC-1 (NCT03145181; NCT04557098), a single-arm, multi-cohort, open-label, multi-center study. The efficacy population consisted of 110 patients who had previously received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and had not received prior BCMA-targeted therapy.

The main efficacy outcome measure was overall response rate (ORR) as determined by the Independent Review Committee assessment using International Myeloma Working Group 2016 criteria. ORR was 61.8%. With a median follow-up of 7.4 months among responders, the estimated duration of response (DOR) rate was 90.6% at 6 months and 66.5% at 9 months.

# Meet The Professor with Dr Raje

**INTRODUCTION**







**MODULE 1: Case Presentations, Part 1**

**MODULE 2: Faculty Survey**

**MODULE 3: Case Presentations, Part 2**







**MODULE 4: Journal Club with Dr Raje**

Regulatory and reimbursement issues aside, what is your preferred pretransplant induction regimen for a younger patient with MM and no high-risk features?

 <b>Dr Fonseca</b>	<b>Daratumumab/KRd</b>	 <b>Dr Lonial</b>	<b>Daratumumab/RVd</b>
 <b>Dr Kumar</b>	<b>RVd</b>	 <b>Dr Raje</b>	<b>Daratumumab/KRd</b>
 <b>Dr Landgren</b>	<b>Daratumumab/KRd</b>	 <b>Dr Richardson</b>	<b>Daratumumab/RVd</b>

KRd = carfilzomib/lenalidomide/dexamethasone; RVd = lenalidomide/bortezomib/dexamethasone

Regulatory and reimbursement issues aside, what would be your preferred induction treatment for a transplant-eligible patient with high-risk (del[17p]) MM?

 Dr Fonseca	Daratumumab/KRd	 Dr Lonial	KRd
 Dr Kumar	Daratumumab/RVd	 Dr Raje	Daratumumab/KRd
 Dr Landgren	Daratumumab/KRd	 Dr Richardson	Daratumumab/KRd

In general, for a patient with standard-risk MM who is receiving maintenance therapy with lenalidomide after autologous stem cell transplant (ASCT), would you offer to discontinue the lenalidomide if a minimal residual disease (MRD) assessment were negative?



**Dr Fonseca**

**Yes, for select patients**



**Dr Lonial**

**No**



**Dr Kumar**

**Yes, for select patients**



**Dr Raje**

**Yes, for select patients**



**Dr Landgren**







**No**



**Dr Richardson**

**No**

Regulatory and reimbursement issues aside, what is your preferred initial regimen for an 80-year-old patient with MM who is transplant ineligible with normal renal function and no high-risk features?

 <b>Dr Fonseca</b>	<b>Daratumumab/Rd</b>	 <b>Dr Lonial</b>	<b>Daratumumab/Rd</b>
 <b>Dr Kumar</b>	<b>Daratumumab/Rd</b>	 <b>Dr Raje</b>	<b>Daratumumab/Rd or Daratumumab/RVd lite</b>
 <b>Dr Landgren</b>	<b>Daratumumab/Rd</b>	 <b>Dr Richardson</b>	<b>Daratumumab/RVd or Daratumumab/RVd lite</b>

Rd = lenalidomide/dexamethasone

When you administer daratumumab to patients with MM, do you generally use the subcutaneous formulation?



**Dr Fonseca**

**Yes**



**Dr Lonial**

**Yes**



**Dr Kumar**

**Yes**



**Dr Raje**

**Yes**



**Dr Landgren**

**Yes**



**Dr Richardson**

**Yes**



**Have you used or would you use isatuximab for a patient who had previously experienced disease progression on daratumumab?**



**Dr Fonseca**

**I have**



**Dr Lonial**

**I have not and  
would not**



**Dr Kumar**

**I have not and  
would not**



**Dr Raje**

**I have not but would  
for the right patient**



**Dr Landgren**







**I have**









**Dr Richardson**

**I have**

# Where in the treatment sequence are you typically incorporating selinexor for your patients with R/R MM?

 <b>Dr Fonseca</b>	<b>Third line</b>	 <b>Dr Lonial</b>	<b>I do not generally use selinexor for patients with MM</b>
 <b>Dr Kumar</b>	<b>Fifth line and beyond</b>	 <b>Dr Raje</b>	<b>Fifth line and beyond</b>
 <b>Dr Landgren</b>	<b>Fifth line and beyond</b>	 <b>Dr Richardson</b>	<b>Third line</b>

## In general, how would you prefer to administer selinexor in the treatment of R/R MM?

 <b>Dr Fonseca</b>	Once a week, usually with carfilzomib	 <b>Dr Lonial</b>	Once a week with bort/dex
 <b>Dr Kumar</b>	Once a week with bort/dex	 <b>Dr Raje</b>	Once a week with bort/dex
 <b>Dr Landgren</b>	Once a week with bort/dex	 <b>Dr Richardson</b>	Once a week with bort/dex

Bort/dex = bortezomib/dexamethasone

Regulatory and reimbursement issues aside, at what point, if any, would you attempt to access venetoclax for a patient with t(11;14) MM?

 Dr Fonseca	Up front	 Dr Lonial	Second line
 Dr Kumar	Second line	 Dr Raje	Second line
 Dr Landgren	Second line	 Dr Richardson	Second line

**Regulatory and reimbursement issues aside, which method do you consider optimal for administering venetoclax to a patient with MM?**



**Dr Fonseca**

**In combination**



**Dr Lonial**

**In combination,  
400 mg**



**Dr Kumar**

**In combination,  
200-400 mg**



**Dr Raje**

**In combination**



**Dr Landgren**

**In combination,  
escalating dose  
(200 mg → 800 mg)**



**Dr Richardson**

**In combination**

# What have you observed in terms of toxicity with venetoclax for MM?



**Dr Fonseca**

**GI side effects**



**Dr Lonial**

**GI side effects**



**Dr Kumar**

**Cytopenias,  
GI side effects**



**Dr Raje**

**Cytopenias,  
GI side effects**



**Dr Landgren**

**GI side effects**



**Dr Richardson**

**Cytopenias**

If CELMoDs (eg, iberdomide, CC-92480) were available, would you use them for a patient who has previously experienced disease progression on standard IMiDs (eg, lenalidomide, pomalidomide)?



Dr Fonseca

Yes



Dr Lonial

Yes



Dr Kumar

Yes



Dr Raje

Yes



Dr Landgren

Yes



Dr Richardson

Yes

# Meet The Professor with Dr Raje

## INTRODUCTION

## MODULE 1: Case Presentations, Part 1

## MODULE 2: Faculty Survey

## MODULE 3: Case Presentations, Part 2

- Dr Narayanan: 83-year-old frail man with standard-risk MM and vertebral fracture; RT/kyphoplasty with disabling bone involvement
- Dr Gupta: 74-year-old woman with MM who developed severe peripheral neuropathy from induction RVd
- Dr Dallas: 57-year-old man with multiple comorbidities and standard-risk MM who receives induction RVd and develops chalazion ocular toxicity

## MODULE 4: Journal Club with Dr Raje



## Case Presentation: 83-year-old frail man with standard-risk MM and vertebral fracture; RT/kyphoplasty with disabling bone involvement



**Dr Vignesh Narayanan (Lone Tree, Colorado)**

**MRI: L3 vertebral fracture**



## Case Presentation: 74-year-old woman with MM who developed severe peripheral neuropathy from induction RVd



**Dr Ranju Gupta (Bethlehem, Pennsylvania)**

## Case Presentation: 57-year-old man with multiple comorbidities and standard-risk MM who receives induction RVd and develops chalazion ocular toxicity



**Dr Jennifer Dallas (Charlotte, North Carolina)**





# Meet The Professor with Dr Raje

**INTRODUCTION**

**MODULE 1: Case Presentations, Part 1**

**MODULE 2: Faculty Survey**

**MODULE 3: Case Presentations, Part 2**

**MODULE 4: Journal Club with Dr Raje**

# Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Perrot A et al.

ASH 2021;Abstract 4095.



*Lancet Haematol* 2022;9:143-61.

# Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group



Noopur S Raje, Elias Anaissie, Shaji K Kumar, Sagar Lonial, Thomas Martin, Morie A Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O'Donnell, Andrew Yee, Jonathan L Kaufman, Adam D Cohen, Laurent Garderet, Ashutosh F Wechalekar, Evangelos Terpos, Navin Khatry, Ruben Niesvizky, Qing Yi, Douglas E Joshua, Tapan Saikia, Nelson Leung, Monika Engelhardt, Mohamad Mothy, Andrew Branagan, Ajai Chari, Anthony J Reiman, Brea Lipe, Joshua Richter, S Vincent Rajkumar, Jesús San Miguel, Kenneth C Anderson, Edward A Stadtmauer, Rao H Prabhala, Phillip L McCarthy, Nikhil C Munshi

Blood Cancer Journal

*Blood Cancer Journal 2021;11:172.*

[www.nature.com/bcj](https://www.nature.com/bcj)

**REVIEW ARTICLE**

**OPEN**



# Lifestyle considerations in multiple myeloma

Yael N. Shapiro<sup>1</sup>, Jeffrey M. Peppercorn<sup>1,2</sup>, Andrew J. Yee<sup>1,2</sup>, Andrew R. Branagan<sup>1,2</sup>, Noopur S. Raje<sup>1,2</sup> and Elizabeth K. O'Donnell<sup>1,2</sup>  



**Warren S Brenner, MD**  
Lynn Cancer Institute  
Boca Raton, Florida



**Yanjun Ma, MD**  
Tennessee Oncology  
Murfreesboro, Tennessee



**Jennifer L Dallas, MD**  
Oncology Specialists of Charlotte  
Charlotte, North Carolina



**Neil Morganstein, MD**  
Atlantic Health System  
Summit, New Jersey



**Ranju Gupta, MD**  
Lehigh Valley Topper Cancer Institute  
Bethlehem, Pennsylvania



**Vignesh Narayanan, MD**  
Colorado Permanente Medical Group  
Lone Tree, Colorado



**Hans Lee, MD**  
The University of Texas  
MD Anderson Cancer Center  
Houston, Texas



**Swati Vishwanathan, MD**  
WVU Medicine  
Bridgeport, West Virginia

# ***Meet The Professor***

## **Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer**

**Tuesday, January 31, 2023  
5:00 PM – 6:00 PM ET**

**Faculty**

**Komal Jhaveri, MD**

**Moderator**

**Neil Love, MD**

***Thank you for joining us!***

***CME and MOC credit information will be emailed  
to each participant within 5 business days.***